Target: Recurrent Glioblastoma Multiforme (reGBM), Colorectal, Ovarian, Pancreatic Cancer and Non-Small Cell Lung Carcinoma (NSCLC)
third-generation, completely synthetic Camptothecin-based compound
Target: Recurrent Glioblastoma Multiforme (reGBM), Colorectal, Ovarian, Pancreatic Cancer and Non-Small Cell Lung Carcinoma (NSCLC)
Vivacitas’ lead development candidate (AR-67) is a third-generation, completely synthetic Camptothecin-based compound. Employing a proprietary synthesis method, AR-67 is a novel lipophilic compound which targets improved efficacy, tolerability, and stability.
New generation of treatment
AR-67 is a silatecan-based, 3rd generation camptothecin with chemical modifications that enhance blood stability and increase the likelihood of cell penetration.
Increased potency
AR-67 is highly lipophilic, meaning that it is readily taken up by the hydrophobic environment of cellular membranes, thus providing significant protection from the extracellular milieu where it would otherwise be broken down to its inactive form.
AR-67 has also demonstrated evidence of crossing the brain-blood barrier, in preclinical and Phase II clinical studies.
Creating a new path forward
AR-67 has shown promise in in vitro, Phase I, and Phase II studies for multiple tumor types and has demonstrated the potential for progression-free survival in patients with recurrent glioblastoma of 6-29 months while significantly reducing severe side effects normally associated with this drug class (e.g., grade 4 diarrhea).
Our Difference
- Potential Increase in bioavailability
- Potential for Increased potency
- Suggestive efficacy signals in initial clinical studies
- Potential improvement in side effect profile
- Potential increase in purity
- Potential for more consistent/reliable supply
- Potential for reduced steps/time/cost to manufacture
- Potential for Quality of life improvement